Barr settles Mirapex and Aggrenox US patent disputes with deals
This article was originally published in Scrip
Executive Summary
Barr Laboratorieshas agreed to settle two US patent disputes with Boehringer Ingelheiminvolving the German company's Parkinson's disease treatment Mirapex (pramipexole dihydrochloride) and the stroke therapy Aggrenox (aspirin plus extended release dipyridamole).